T1	Participants 173 278	elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies.
T2	Participants 452 516	elderly patients with advanced, low-grade non-Hodgkin's lymphoma
T3	Participants 675 726	One hundred and fifty-five patients were randomized
